Desmopressin (DDAVP) Responsiveness in Children with von Willebrand Disease

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 11, 2003, Pages 874-879

  Revel Vilk, Shoshana ^a   Schmugge, Markus ^a   Carcao, Manuel D ^a,b   Blanchette, Phillip ^a   Rand, Margaret L ^a,c   Blanchette, Victor S ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

DDAVP; Desmopressin; Von Willebrand disease

Indexed keywords

BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; RISTOCETIN; VON WILLEBRAND FACTOR;

AGE; BLEEDING; BLOOD TRANSFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SCHOOL CHILD; TREATMENT INDICATION; VON WILLEBRAND DISEASE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; VON WILLEBRAND DISEASE;

EID: 0242693232     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200311000-00010     Document Type: Review

References (35)

1. Lethagen S. Desmopressin: a haemostatic drug: state of the art review. Eur J Anaesthesiol Suppl. 1997;14:1-9.
2. Mannucci PM, Åberg M, Nilsson IM, et al. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol. 1975;30:81-93.
3. Mannucci PM, Pareti FI, Holmberg L, et al. Studies on the prolonged bleeding time in von Willebrand disease. J Lab Clin Med. 1976;88:662-671.
4. Sakariassen KS, Cattaneo M, van der Berg A, et al. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood. 1984;64:229-236.
5. Balduini CL, Noris P, Belletti S, et al. In vitro and in vivo effects of desmopressin on platelet function. Haematologica. 1999;84:891-896.
6. Keularts IMLW, Hamulyak K, Hemker HC, et al. The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients. Thromb Haemost. 2000;84: 638-642.
7. Mannucci PM. How I treat patients with von Willebrand disease. Blood. 2001;97:1915-1919.
8. Sutor AH. Desmopressin (DDAVP) in bleeding disorders of childhood. Semin Thromb Hemost. 1998;24:555-566.
9. Cattaneo M. Review of clinical experience of desmopressin in patients with congenital and acquired bleeding disorders. Eur J Anaesthesiol Suppl. 1997;14:10-14.
10. Association of Haemophilia Clinic Directors of Canada. Israels SJ, Poon MC, Lillicrap DP, principal co-authors. Haemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Can Med Assoc J. 1995;153:19-25.
11. Sutor AH. DDAVP is not a panacea for children with bleeding disorders. Br J Haematol. 2000;108:217-227.
12. Mannucci PM, Canciani MT, Rota L, et al. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease. Br J Haematol. 1981;47:283-293.
13. Kundu SK, Heilmann EJ, Sio R, et al. Description of an in vitro Platelet Function Analyzer PFA-100TM. Semin Thromb Hemost. 1995;21(Suppl 2):106-112.
14. Mammen EF, Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100™ system. Semin Thromb Hemost. 1995;21(Suppl 2):113-120.
15. Carcao MD, Blanchette VS, Dean JA, et al. The platelet function analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children. Br J Haematol. 1998;101:70-73.
16. Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood. 1998;91:1325-1331.
17. Dean JA, Blanchette VS, Carcao MD, et al. von Willebrand disease in a pediatric-based population: comparison of type I diagnostic criteria and use of the PFA-100® and a von Willebrand factor/collagen-binding assay. Thromb Haemost. 2000;84:401-409.
18. Cattaneo M, Federici AB, Lecchi A, et al. Evaluation of the PFA-100® system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost. 1999;82:35-39.
19. Favaloro EJ, Kershaw G, Bukuya M, et al. Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies. Haemophilia. 2001;7:180-189.
20. Fressinaud E, Veyradier A, Sigaud M, et al. Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates. Br J Haematol. 1999;106:777-783.
21. Sadler JE, Mannucci PM, Bemtrop E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84:160-174.
22. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966;15:45-52.
23. Howard MA, Firkin BG. Ristocetin: A new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh. 1971;26:362-369.
24. Federici AB, Bucciarelli P, Siboni SM, et al. Biological response to desmopressin and its use in clinical practice: A retrospective study on 774 Italian patients with mild and severe type 1 and 2 von Willebrand disease [abstract P1813]. Thromb Haemost 2001; July Suppl (CD version only), XVIIIth Congress of the International Society of Thrombosis and Haemastosis, Paris, France.
25. de la Fuente B, Kasper CK, Rickles FR, et al. Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin. Ann Intern Med. 1985;103:6-14.
26. Rodeghiero F, Castaman G, Di Bona E, et al. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood. 1989;74:1997-2000.
27. Nolan B, White B, Smith J, et al. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders. Br J Haematol. 2000;109:865-869.
28. Revel-Vilk S, Blanchette VS, Sparling C, et al. DDAVP challenge tests in boys with mild/moderate haemophilia A. Br J Haematol. 2002;117:947-951.
29. Rushton HG, Belman BA, Zantoz MR, et al. The influence of small functional bladder capacity and other predictors on the response to desmopressin in the management of monosymptomatic nocturnal enuresis. J Urol. 1996;156:651-655.
30. Ervin GM. Perinatal fluid and electrolyte regulation: role of arginine vasopressin. Semin Perinat. 1988;12:134-142.
31. Francis JD, Leary T, Nibilett DJ. Convulsions and respiratory arrest in association with desmopressin administration for the treatment of a bleeding tonsil in a child with borderline hemophilia. Acta Anaesthesiol Scand. 1999;43:870-873.
32. Smith TJ, Gill JC, Ambruso DR, et al. Hyponatremia and seizures in young children given DDAVP. Am J Hematol. 1989;31:199-202.
33. Delifanian K, Zawada ET Jr. DDAVP-associated hyponatremia. S D J Med. 2001;54:255-256.
34. Lebl J, Kolská M, Zavacká A, et al. Cerebral oedema in enuretic children during low-dose desmopressin: a preventable complication. Eur J Pediatr. 2001;160:159-162.
35. Cohen AJ, Kessler CM, Ewenstein BM. Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centers of North America. Haemophilia. 2001;7:235-241.